2nd study testing a COVID-19 antibody drug has a setback

Advertisement

Advertise with us

For the second time, a study testing an experimental antibody drug for COVID-19 has been paused to investigate a possible safety issue in hospitalized patients.

Read this article for free:


or

Already have an account? Log in here »

To continue reading, please subscribe:

Subscribe and receive a limited-edition Free Press branded hat or tote.

Digital Subscription

One year of digital access for only $205*

  • Enjoy unlimited reading on winnipegfreepress.com
  • Read the E-Edition, our digital replica newspaper
  • Access News Break, our award-winning app
  • Play interactive puzzles

*First annual payment billed as $205.00 + GST for one year. This annual subscription will automatically renew at $233.00 + GST every 52 weeks (10% off the regular annual price of $259.35). Offer available to new and qualified returning subscribers only. Cancel any time.

To continue reading, please subscribe:

Add Free Press access to your Brandon Sun subscription for only an additional

$1 for the first 4 weeks*

  • Enjoy unlimited reading on winnipegfreepress.com
  • Read the E-Edition, our digital replica newspaper
  • Access News Break, our award-winning app
  • Play interactive puzzles
Start now

*Your next Brandon Sun subscription payment will increase by $1.00 and you will be charged $17.95 plus GST for four weeks. After four weeks, your payment will increase to $24.95 plus GST every four weeks.

Hey there, time traveller!
This article was published 30/10/2020 (2130 days ago), so information in it may no longer be current.

For the second time, a study testing an experimental antibody drug for COVID-19 has been paused to investigate a possible safety issue in hospitalized patients.

Regeneron Pharmaceuticals Inc. said Friday that independent monitors had recommended placing on hold enrolment of the most severely ill patients — those who need intense oxygen treatment or breathing machines — because of a potential safety problem and unfavourable balance of risks and benefits.

The study can continue to test the two-antibody drug combo in hospitalized patients who need little or no extra oxygen, the monitors said. Other studies in mild or moderately ill people also are continuing.

In this undated image from video provided by Regeneron Pharmaceuticals on Friday, Oct. 2, 2020, scientists work with a bioreactor at a company facility in New York state, for efforts on an experimental coronavirus antibody drug. Antibodies are proteins the body makes when an infection occurs; they attach to a virus and help the immune system eliminate it. (Regeneron via AP)
In this undated image from video provided by Regeneron Pharmaceuticals on Friday, Oct. 2, 2020, scientists work with a bioreactor at a company facility in New York state, for efforts on an experimental coronavirus antibody drug. Antibodies are proteins the body makes when an infection occurs; they attach to a virus and help the immune system eliminate it. (Regeneron via AP)

Antibodies are proteins the body makes when an infection occurs; they attach to a virus and help it be eliminated. But it can take several weeks for the most effective ones to form. The experimental drugs aim to help immediately, by supplying concentrated versions of one or two antibodies that worked best against the coronavirus in lab and animal tests.

Earlier this month, a different group of monitors recommended pausing enrolment in a U.S. National Institutes of Health study testing an Eli Lilly antibody drug to investigate a possible safety issue in hospitalized patients. On Monday, the NIH said no safety problem had been verified, but they stopped the study because the drug didn’t seem to work in that situation.

“These kinds of results are informing us about the timing of the benefit,” said Dr. Myron Cohen, a University of North Carolina virologist who advises the government on COVID-19 treatments.

Tests in animals suggest that antibody drugs work best when given early in infection to lower the amount of virus, he said. Once someone is very sick, the drugs may not help, but it’s too soon to know if that’s the case, he said.

Doctors already know that timing can matter when it comes to COVID-19 treatments. Studies suggest that dexamethasone and other steroids can lower the risk of death when given to very sick patients to tamp down an over-active immune system, but they may be harmful for those who are only mildly ill.

Lilly and Regeneron have asked the Food and Drug Administration to allow emergency use of their experimental antibody drugs for mild and moderately ill patients who don’t need hospitalization. President Donald Trump got the Regeneron drug when he was sickened earlier this month.

Regeneron said it would share Friday’s advice from independent monitors with the FDA and leaders of a separate study in the United Kingdom testing its drug in hospitalized patients.

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

Report Error Submit a Tip

More Stories

New businesses start to creep up in former Winnipeg Slurpee shops

Tiago Resko 5 minute read Preview

New businesses start to creep up in former Winnipeg Slurpee shops

Tiago Resko 5 minute read Thursday, Aug. 27, 2026

The remnants of 7-Eleven can still be seen as new businesses move into spaces where Slurpee machines and taquitos once ruled.

As fresh paint dries on several new ventures — such as a pizza place and a convenience store with a name that might make a customer do a double-take — holes across Winnipeg once occupied by the international convenience chain are slowly being filled.

Business at a Domino’s Pizza in Elmwood, formerly a 7-Eleven, has been booming since it opened June 1, the store manager said.

“The issues that 7-Eleven would have had might be different than what we would have. They were dealing with a lot of theft where people can just walk in and out, but Domino’s isn’t set up that way,” said Paul Hemmerling.

Read
Thursday, Aug. 27, 2026

Puzzles Palace

1 minute read Monday, Jul. 27, 2026

To solve our puzzles, please subscribe with this special offer: |

River City Sports Bar & Events Centre opens its many doors in Polo Park area

Aaron Epp 4 minute read Preview

River City Sports Bar & Events Centre opens its many doors in Polo Park area

Aaron Epp 4 minute read Friday, Aug. 28, 2026

Winnipeggers have a new option for food and entertainment in the Polo Park area.

River City Sports Bar & Events Centre celebrated its grand opening on Friday (with its soft opening to the public today). Located at 300-1395 Ellice Ave., the 15,000-square-foot, multi-purpose facility includes a sports bar that hosts live music, comedy, karaoke and major sporting events.

The building also includes a poker room and an events centre for weddings, socials, conferences and other private functions.

“The idea is to be a step above — give Winnipeg a new experience,” co-owner Mike Rozak said Friday. “We’re up for anything, as long as it’s legal.”

Read
Friday, Aug. 28, 2026

2nd study testing a COVID-19 antibody drug has a setback

Marilynn Marchione, The Associated Press 3 minute read Preview

2nd study testing a COVID-19 antibody drug has a setback

Marilynn Marchione, The Associated Press 3 minute read Friday, Oct. 30, 2020

For the second time, a study testing an experimental antibody drug for COVID-19 has been paused to investigate a possible safety issue in hospitalized patients.

Regeneron Pharmaceuticals Inc. said Friday that independent monitors had recommended placing on hold enrolment of the most severely ill patients -- those who need intense oxygen treatment or breathing machines -- because of a potential safety problem and unfavourable balance of risks and benefits.

The study can continue to test the two-antibody drug combo in hospitalized patients who need little or no extra oxygen, the monitors said. Other studies in mild or moderately ill people also are continuing.

Antibodies are proteins the body makes when an infection occurs; they attach to a virus and help it be eliminated. But it can take several weeks for the most effective ones to form. The experimental drugs aim to help immediately, by supplying concentrated versions of one or two antibodies that worked best against the coronavirus in lab and animal tests.

Read
Friday, Oct. 30, 2020

Summer Reading Challenge concludes with more musings from young readers

8 minute read Preview

Summer Reading Challenge concludes with more musings from young readers

8 minute read Yesterday at 6:00 AM CDT

Another Free Press Summer Reading Challenge for Kids is in the books, but before we turn the page completely, there are a few more reviews written by our young readers to share.

Participating readers were tasked to write down their thoughts about any of the books on the Summer Reading Challenge’s three reading lists; with a range of formats (novels, graphic novels, books with pictures), themes and reading levels to choose from, budding reviewers of all ages were eager to share their opinion.

Those registered for the challenge received reading resources and activities throughout the summer, from word searches or puzzles based on the content of the books to a set of discussion questions and, in one instance, a special video from an author.

There were also more creative activities meant to engage readers’ critical thinking skills, all of which were free to access for anyone who signed up for the challenge.

Read
Yesterday at 6:00 AM CDT

Doctor pays $500K to revamp courtyard at care home where he works

By Zoe Pierce 4 minute read Preview

Doctor pays $500K to revamp courtyard at care home where he works

By Zoe Pierce 4 minute read Thursday, Aug. 27, 2026

Fifty years after Dr. Pravinsagar Mehta began caring for residents at Actionmarguerite, a courtyard he had long watched deteriorate is getting a new life after he and his wife committed $500,000 to its redevelopment and long-term maintenance.

Read
Thursday, Aug. 27, 2026